• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Recombinant Vaccines Market Share

    ID: MRFR/Pharma/4672-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Recombinant Vaccines Market Research Report Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) - Global Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Recombinant Vaccines Market Infographic
    Purchase Options

    Market Share

    Recombinant Vaccines Market Share Analysis

    Within the broad pharmaceutical and biotechnology sector, the Recombinant Vaccines market employs various strategic methods aimed at gaining competitive edge in addition to responding to changing vaccine development landscapes. A chief tactic is through ongoing research and innovation in recombinant vaccines’ manufacturing. They spend a lot of money on research and development for vaccines made through genetic engineering that can enhance safety, have better efficacy rates, as well as offer more extensive protection against diseases targeted. Consequently, these companies bring advanced solutions into the market to distinguish themselves from competition and occupy a huge share of the prices of this kind of vaccines.

    Recombinant Vaccines sector’s positioning on market share is determined by pricing strategies. Due to their significance in public health, some companies adopt different pricing models for their vaccines. Some firms may choose competitive pricing so that many people can afford their medicines while others might prefer value-based pricing where they sell at higher prices just because recombinant vaccines have distinct advantages over the other types of vaccines that are currently available in the market. This balance between how much it costs and how valuable it is guarantees spread of such innovations across most populations but also demands profits.

    Success within the Recombinant Vaccines market depends heavily on collaborations and partnerships. Partnerships with research institutions, governmental bodies or global organizations assist companies during vaccine development and distribution process thereby enabling them pool resources together with knowledge that relates to complexities involved in doing so. Such collaborative works expedite both scientific investigations as well as regulatory processes besides offering opportunities for global marketing thus strengthening supply chains which makes businesses major players within Recombinant Vaccines industry.

    Influencing any given segment’s market share in Recombinant Vaccines necessitates having proper marketing plus branding strategies implemented diligently by companies operating there. Companies run heavy marketing campaigns geared towards communicating product benefits to clients, creating awareness among healthcare providers and general population about its availability while establishing trust of people towards its safety along with effectiveness. The overall idea is to get involved in education, public relations and global health forums among other things that will create a strong brand presence, thus influencing market share and positioning within the competitive arena.

    For firms aiming at consolidating their market share in the Recombinant Vaccines segment, geographical expansion is an important consideration. Picking locations with high prevalence rates of diseases and adapting strategies that are appropriate to local needs are imperative. When dealing with different parts of the world, businesses must tailor products so as to align them with respective cultural backgrounds or regulatory environments. In this way, it becomes possible for companies to penetrate markets successfully by tailoring their product offerings, distribution channels as well as marketing approaches depending on the distinct cultural settings and regulations existing there.

    Investment in post-market surveillance, pharmacovigilance and public health interventions is also essential in order to keep up as well as expand dominance within Recombinant Vaccines industry. Constant monitoring of vaccine safety plus efficacy alongside effective patient education programs enhance trust from professionals within healthcare industry including common people who use vaccines on patients. Therefore, vendors’ continuous commitment towards safety together with general welfare is what maintains their sales levels ensuring they remain recognized stakeholders within the recombinant vaccines industry.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the growth rate of the global recombinant vaccines market?

    The global recombinant vaccines market is expected to expand at 6.24% CAGR from 2024 to 2032.

    Who are the major players of the global recombinant vaccines market?

    Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Daiichi Sankyo, Serum Institute of India Pvt. Ltd, Emergent Bio Solutions, Inc., Sanofi Pasteur SA, and Abiomed are major players in the global recombinant vaccines market.

    What are the restraining factors of the global recombinant vaccines market?

    High costs of vaccines and huge risks associated with attenuated vaccines are factors which can hamper the global recombinant vaccines market.

    Which region can dominate in the global recombinant vaccines market?

    The global recombinant vaccines market is led by the Americas due to rapid strides in molecular biology in the region.

    What are major drivers of the global recombinant vaccines market?

    High prevalence of diseases and large number of approvals are major drivers of the global recombinant vaccines market.

    Market Summary

    The Global Recombinant Vaccines Market is projected to experience substantial growth from 0.36 USD Billion in 2024 to 1.94 USD Billion by 2035.

    Key Market Trends & Highlights

    Global Recombinant Vaccines Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate of 16.56% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.94 USD Billion, indicating robust expansion.
    • In 2024, the market is valued at 0.36 USD Billion, highlighting its current size and potential for growth.
    • Growing adoption of recombinant vaccine technology due to increasing awareness of vaccine-preventable diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.36 (USD Billion)
    2035 Market Size 1.94 (USD Billion)
    CAGR (2025-2035) 16.56%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.

    Market Trends

    The ongoing advancements in biotechnology are likely to enhance the efficacy and accessibility of recombinant vaccines, thereby playing a crucial role in global health initiatives.

    World Health Organization (WHO)

    Recombinant Vaccines Market Market Drivers

    Government Initiatives and Funding

    Government initiatives and funding significantly influence the Global Recombinant Vaccines Market Industry. Many countries are increasing their investments in vaccine research and development to combat infectious diseases. For example, national health agencies are allocating substantial budgets to support the development of recombinant vaccines, which are often seen as a cost-effective solution for public health challenges. These initiatives not only facilitate the advancement of vaccine technology but also encourage collaboration between public and private sectors. As governments recognize the critical role of vaccines in safeguarding public health, the financial backing for recombinant vaccine projects is expected to grow, thereby enhancing the market landscape.

    Rising Demand for Preventive Healthcare

    The Global Recombinant Vaccines Market Industry experiences a notable surge in demand for preventive healthcare solutions. As populations become increasingly aware of the importance of vaccination in preventing infectious diseases, the market is projected to grow from 0.36 USD Billion in 2024 to an estimated 1.94 USD Billion by 2035. This growth indicates a compound annual growth rate (CAGR) of 16.56% from 2025 to 2035. Governments and health organizations are actively promoting vaccination programs, which further drives the demand for recombinant vaccines. This trend reflects a broader shift towards proactive health management, underscoring the significance of vaccines in public health strategies.

    Increasing Incidence of Infectious Diseases

    The rising incidence of infectious diseases is a crucial driver of the Global Recombinant Vaccines Market Industry. With the emergence of new pathogens and the resurgence of previously controlled diseases, the need for effective vaccination strategies has never been more pressing. This trend is particularly evident in regions experiencing outbreaks, where recombinant vaccines can provide rapid responses to emerging health threats. The World Health Organization and other health bodies emphasize the importance of vaccination in controlling disease spread. Consequently, the demand for recombinant vaccines is likely to increase, as they offer a viable solution to mitigate the impact of infectious diseases on global health.

    Technological Advancements in Vaccine Development

    Technological innovations play a pivotal role in shaping the Global Recombinant Vaccines Market Industry. Advances in genetic engineering and biotechnology have streamlined the development of recombinant vaccines, enhancing their efficacy and safety profiles. For instance, the use of recombinant DNA technology allows for the rapid production of vaccines tailored to specific pathogens. This capability not only accelerates the vaccine development process but also ensures a more robust immune response. As research institutions and pharmaceutical companies continue to invest in these technologies, the market is likely to witness an influx of novel vaccines, further propelling its growth and expanding the range of diseases that can be effectively targeted.

    Growing Public Awareness and Acceptance of Vaccines

    Public awareness and acceptance of vaccines are essential factors driving the Global Recombinant Vaccines Market Industry. Educational campaigns and outreach programs have significantly improved understanding of vaccine benefits, leading to higher vaccination rates. This trend is particularly evident in developing countries, where initiatives aimed at increasing vaccine literacy have resulted in greater public trust in vaccination programs. As communities become more informed about the role of vaccines in preventing diseases, the demand for recombinant vaccines is expected to rise. This growing acceptance not only supports public health objectives but also encourages investment in vaccine development, further stimulating market growth.

    Market Segment Insights

    Regional Insights

    Key Companies in the Recombinant Vaccines Market market include

    Industry Developments

    Future Outlook

    Recombinant Vaccines Market Future Outlook

    The Global Recombinant Vaccines Market is projected to grow at a 16.56% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising healthcare investments.

    New opportunities lie in:

    • Develop novel adjuvants to enhance vaccine efficacy and market differentiation.
    • Expand production capabilities in emerging markets to meet rising global demand.
    • Invest in digital health solutions for vaccine distribution and patient engagement.

    By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in global healthcare innovation.

    Market Segmentation

    Market Segmentation

    Recombinant Vaccines Market Segmentation   

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 0.29 (USD Billion)
    Market Size 2024 0.36 (USD Billion)
    Market Size 2032 1.62 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.24 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.
      Key Market Opportunities ·  Raising awareness of healthcare, favorable reimbursement policies ·  Increasing innovations in research and development of drugs, and vaccines ·  Rising average income of individuals
      Key Market Drivers ·  Increasing technical advanced devices ·  Increasing number of regulatory approvals ·  The high prevalence of infectious diseases ·  Growing penetration of key market players

    FAQs

    What is the growth rate of the global recombinant vaccines market?

    The global recombinant vaccines market is expected to expand at 6.24% CAGR from 2024 to 2032.

    Who are the major players of the global recombinant vaccines market?

    Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Daiichi Sankyo, Serum Institute of India Pvt. Ltd, Emergent Bio Solutions, Inc., Sanofi Pasteur SA, and Abiomed are major players in the global recombinant vaccines market.

    What are the restraining factors of the global recombinant vaccines market?

    High costs of vaccines and huge risks associated with attenuated vaccines are factors which can hamper the global recombinant vaccines market.

    Which region can dominate in the global recombinant vaccines market?

    The global recombinant vaccines market is led by the Americas due to rapid strides in molecular biology in the region.

    What are major drivers of the global recombinant vaccines market?

    High prevalence of diseases and large number of approvals are major drivers of the global recombinant vaccines market.

    1. Report
      1. Prologue
    2. Market Introduction
      1. Definition
        1. Research
        2. Assumptions
        3. Limitations
      2. 2.2
      3. Scope of the Study
      4. Objective
      5. 3.
      6. Research Methodology
      7. Introduction
      8. 3.2
      9. Primary Research
      10. Secondary Research
      11. Market Size Estimation
    3. Market
      1. Dynamics
      2. Drivers
      3. 4.2
      4. Restraints
      5. Opportunities
      6. Challenges
      7. Macroeconomic Indicators
      8. Technology Trends & Assessment
    4. Market
      1. Factor Analysis
      2. Porter’s Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Threat of New Entrants
        3. Threat of Substitutes
        4. Intensity of Rivalry
      3. 5.1.2
      4. Bargaining Power of Buyers
      5. 5.2
      6. Value Chain Analysis
      7. Investment Feasibility Analysis
      8. Pricing Analysis
    5. Global
    6. Recombinant Vaccines Market, by Route of Administration
      1. Introduction
      2. Intramuscular and Subcutaneous
      3. Administration
      4. • Market Estimates & Forecast, 2020–2027
    7. • Market Estimates & Forecast, by Region/Country,
      1. Oral Administration
      2. Market Estimates & Forecast, 2020–2027
    8. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. Other Routes of Administration
      2. Market Estimates & Forecast, 2020–2027
    9. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. 7.
    10. Global Recombinant Vaccines Market, by Type
      1. Introduction
      2. Subunit recombinant vaccines
      3. • Market
      4. Estimates & Forecast, 2020–2027
    11. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. 7.3
      2. Attenuated recombinant vaccines
      3. • Market Estimates
      4. & Forecast, 2020–2027
      5. • Market
      6. Estimates & Forecast, by Region/Country, 2020–2027
      7. Vector recombinant
      8. vaccines
      9. • Market
      10. Estimates & Forecast, 2020–2027
      11. • Market Estimates & Forecast,
      12. by Region/Country, 2020–2027
    12. Global Recombinant
    13. Vaccines Market, by Disease
      1. Introduction
      2. 8.2
      3. Pneumococcal Disease
      4. • Market Estimates &
      5. Forecast, 2020–2027
      6. • Market
      7. Estimates & Forecast, by Region/Country, 2020–2027
      8. 8.3
      9. Cancer
      10. • Market Estimates & Forecast, 2020–2027
    14. • Market Estimates & Forecast, by Region/Country,
      1. Hepatitis B
      2. • Market
      3. Estimates & Forecast, 2020–2027
    15. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. 8.5
      2. Influenza
      3. • Market Estimates & Forecast, 2020–2027
    16. • Market Estimates & Forecast, by Region/Country,
      1. 8.6
      2. HPV (Human papillomavirus)
      3. Market Estimates & Forecast, 2020–2027
      4. • Market Estimates & Forecast, by
      5. Region/Country, 2020–2027
      6. 8.7
      7. DPT
      8. Market Estimates & Forecast, 2020–2027
      9. • Market Estimates & Forecast, by
      10. Region/Country, 2020–2027
      11. 8.8
      12. Others
      13. • Market
      14. Estimates & Forecast, 2020–2027
    17. • Market Estimates & Forecast, by Region/Country,
    18. Global Recombinant Vaccines Market,
      1. by End-User
      2. Introduction
      3. Hospitals
      4. & Clinics
      5. • Market Estimates & Forecast, 2020–2027
    19. • Market Estimates & Forecast, by Region/Country,
      1. Pediatrics
      2. • Market
      3. Estimates & Forecast, 2020–2027
    20. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. 9.4
      2. Adults
      3. • Market Estimates
      4. & Forecast, 2020–2027
      5. • Market
      6. Estimates & Forecast, by Region/Country, 2020–2027
      7. Veterinary
      8. • Market Estimates & Forecast, 2020–2027
    21. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. Market Estimates & Forecast, 2020–2027
    22. Poultry
    23. Market Estimates & Forecast, by Region/Country, 2020–2027
      1. • Market Estimates & Forecast, 2020–2027
    24. Livestock
    25. • Market Estimates & Forecast, by Region/Country,
      1. • Market
      2. Estimates & Forecast, 2020–2027
    26. Others
    27. Market Estimates & Forecast, by Region/Country, 2020–2027
    28. Global Recombinant Vaccines Market, by Region
      1. 10.1
      2. Introduction
      3. Americas
    29. Market Estimates & Forecast, by Region, 2020–2027
    30. Market Estimates & Forecast, by Type, 2020–2027
    31. Market Estimates & Forecast, by Disease, 2020–2027
    32. Market Estimates & Forecast, by End-User, 2020–2027
      1. 10.2.1
      2. North America
      3. • Market Estimates & Forecast,
      4. by Country, 2020–2027
      5. • Market Estimates &
      6. Forecast, by Type, 2020–2027
      7. • Market Estimates
      8. & Forecast, by Disease, 2020–2027
      9. • Market
      10. Estimates & Forecast, by End-User, 2020–2027
      11. 10.2.1.1
      12. U.S.
    33. • Market Estimates & Forecast, by Type,
      1. • Market Estimates & Forecast, by
      2. Disease, 2020–2027
      3. • Market Estimates &
      4. Forecast, by End-User, 2020–2027
    34. Canada
    35. • Market Estimates & Forecast, by Type, 2020–2027
    36. • Market Estimates & Forecast, by Disease, 2020–2027
    37. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates
      2. & Forecast, by Type, 2020–2027
      3. • Market Estimates
      4. & Forecast, by Disease, 2020–2027
      5. • Market
      6. Estimates & Forecast, by End-User, 2020–2027
    38. South America
      1. Europe
    39. • Market Estimates & Forecast, by Region, 2020–2027
    40. • Market Estimates & Forecast, by Type, 2020–2027
    41. • Market Estimates & Forecast, by Disease, 2020–2027
    42. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates
      2. & Forecast, by Country, 2020–2027
      3. • Market
      4. Estimates & Forecast, by Type, 2020–2027
      5. • Market
      6. Estimates & Forecast, by Disease, 2020–2027
    43. Western Europe
    44. Market Estimates & Forecast, by End-User, 2020–2027
      1. 10.3.1.1
      2. Germany
      3. • Market Estimates & Forecast, by
      4. Type, 2020–2027
      5. • Market Estimates & Forecast,
      6. by Disease, 2020–2027
      7. • Market Estimates
      8. & Forecast, by End-User, 2020–2027
    45. France
    46. • Market Estimates & Forecast, by Type, 2020–2027
    47. • Market Estimates & Forecast, by Disease, 2020–2027
    48. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates
      2. & Forecast, by Type, 2020–2027
      3. • Market Estimates
      4. & Forecast, by Disease, 2020–2027
      5. • Market
      6. Estimates & Forecast, by End-User, 2020–2027
      7. 10.3.1.4
      8. Italy
    49. U.K.
    50. • Market Estimates & Forecast, by Type,
      1. • Market Estimates & Forecast, by
      2. Disease, 2020–2027
      3. • Market Estimates &
      4. Forecast, by End-User, 2020–2027
    51. Spain
    52. • Market Estimates & Forecast, by Type, 2020–2027
    53. • Market Estimates & Forecast, by Disease, 2020–2027
    54. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market
      2. Estimates & Forecast, by Type, 2020–2027
      3. • Market
      4. Estimates & Forecast, by Disease, 2020–2027
    55. Rest of Western Europe
    56. Market Estimates & Forecast, by End-User, 2020–2027
      1. 10.3.2
      2. Eastern Europe
      3. • Market Estimates & Forecast,
      4. by Type, 2020–2027
      5. • Market Estimates & Forecast,
      6. by Disease, 2020–2027
      7. • Market Estimates
      8. & Forecast, by End-User, 2020–2027
      9. Asia Pacific
    57. • Market Estimates & Forecast, by Country, 2020–2027
    58. • Market Estimates & Forecast, by Type, 2020–2027
    59. • Market Estimates & Forecast, by Disease, 2020–2027
    60. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates
      2. & Forecast, by Type, 2020–2027
      3. • Market Estimates
      4. & Forecast, by Disease, 2020–2027
      5. • Market
      6. Estimates & Forecast, by End-User, 2020–2027
    61. Japan
    62. China
    63. • Market Estimates & Forecast, by Type, 2020–2027
    64. • Market Estimates & Forecast, by Disease, 2020–2027
    65. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates
      2. & Forecast, by Type, 2020–2027
      3. • Market Estimates
      4. & Forecast, by Disease, 2020–2027
      5. • Market
      6. Estimates & Forecast, by End-User, 2020–2027
    66. India
    67. Australia
    68. • Market Estimates & Forecast, by Type, 2020–2027
    69. • Market Estimates & Forecast, by Disease, 2020–2027
    70. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market
      2. Estimates & Forecast, by Type, 2020–2027
      3. • Market
      4. Estimates & Forecast, by Disease, 2020–2027
    71. Republic of Korea
    72. Market Estimates & Forecast, by End-User, 2020–2027
      1. 10.4.6
      2. Rest of Asia Pacific
      3. • Market Estimates &
      4. Forecast, by Type, 2020–2027
      5. • Market Estimates
      6. & Forecast, by Disease, 2020–2027
      7. • Market
      8. Estimates & Forecast, by End-User, 2020–2027
      9. The
        1. United
        2. Saudi
      10. Middle East & Africa
      11. • Market Estimates & Forecast,
      12. by Region, 2020–2027
      13. • Market Estimates &
      14. Forecast, by Type, 2020–2027
      15. • Market Estimates
      16. & Forecast, by Disease, 2020–2027
      17. • Market
      18. Estimates & Forecast, by End-User, 2020–2027
      19. Arab Emirates
      20. • Market Estimates & Forecast, by
      21. Type, 2020–2027
      22. • Market Estimates & Forecast,
      23. by Disease, 2020–2027
      24. • Market Estimates
      25. & Forecast, by End-User, 2020–2027
      26. Arabia
    73. • Market Estimates & Forecast, by Type, 2020–2027
    74. • Market Estimates & Forecast, by Disease, 2020–2027
    75. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates &
      2. Forecast, by Type, 2020–2027
      3. • Market Estimates
      4. & Forecast, by Disease, 2020–2027
      5. • Market
      6. Estimates & Forecast, by End-User, 2020–2027
    76. Oman
    77. Kuwait
    78. • Market Estimates & Forecast, by Type, 2020–2027
    79. • Market Estimates & Forecast, by Disease, 2020–2027
    80. • Market Estimates & Forecast, by End-User, 2020–2027
      1. • Market Estimates
      2. & Forecast, by Type, 2020–2027
      3. • Market Estimates
      4. & Forecast, by Disease, 2020–2027
      5. • Market
      6. Estimates & Forecast, by End-User, 2020–2027
      7. of the Middle East & Africa
      8. • Market Estimates &
      9. Forecast, by Type, 2020–2027
      10. • Market Estimates
      11. & Forecast, by Disease, 2020–2027
      12. • Market
      13. Estimates & Forecast, by End-User, 2020–2027
    81. Qatar
    82. Rest
    83. Company
      1. Landscape
      2. Introduction
      3. Market Share Analysis
      4. 11.3
      5. Key Development & Strategies
      6. 11.3.1
      7. Key Developments
    84. Company Profiles
      1. Astellas Pharma Inc
        1. Route of
        2. Financials
        3. SWOT Analysis
        4. Company Overview
        5. Route of Administration Overview
        6. Financial Overview
        7. SWOT Analysis
      2. 12.1.1
      3. Company Overview
      4. Administration Overview
      5. 12.2
      6. CSL Limited
      7. 12.2.4
      8. Key Developments
      9. Emergent BioSolutions, Inc.
        1. Route of
        2. Financial
        3. Key Development
      10. 12.3.1
      11. Company Overview
      12. Administration Overview
      13. Overview
      14. 12.3.5
      15. SWOT Analysis
      16. GlaxoSmithKline
        1. Company Overview
        2. Key Development
        3. SWOT Analysis
        4. Company Overview
        5. Route of Administration Overview
        6. Financial overview
      17. 12.4.2
      18. Route of Administration/Business Segment Overview
      19. 12.4.3
      20. Financial Overview
      21. 12.5
      22. Johnson & Johnson (U.S.)
      23. 12.5.4
      24. Key Developments
      25. Mitsubishi
        1. Company Overview
        2. Route of Administration Overview
        3. Financial Overview
      26. Tanabe Pharma Corporation
      27. 12.6.4
      28. Key Developments
      29. Merck &
        1. Overview
        2. Key Developments
        3. SWOT Analysis
        4. Overview
        5. Route of Administration Overview
        6. Financials
        7. SWOT Analysis
      30. Co., Inc.
      31. 12.7.2
      32. Route of Administration Overview
      33. 12.7.3
      34. Financials
      35. 12.8
      36. Pfizer, Inc..
      37. 12.8.4
      38. Key Developments
      39. Sanofi Pasteur SA
        1. Overview
        2. Route of Administration Overview
        3. Financials
        4. SWOT Analysis
      40. 12.9.4
      41. Key Developments
      42. Serum Institute of India Pvt. Ltd
        1. Route of Administration
        2. Financials
        3. Key Developments
      43. 12.10.1
      44. Overview
      45. Overview
      46. 12.10.5
      47. SWOT Analysis
      48. Bavarian Nordic
        1. Overview
        2. Key Developments
        3. SWOT Analysis
        4. Overview
        5. Route of Administration Overview
        6. Financials
        7. SWOT Analysis
      49. 12.11.2
      50. Route of Administration Overview
      51. 12.11.3
      52. Financials
      53. 12.12
      54. Mitsubishi Tanabe Pharma Corporation
      55. 12.12.4
      56. Key Developments
      57. Daiichi Sankyo
        1. Overview
        2. Key Developments
        3. SWOT Analysis
      58. 12.13.2
      59. Route of Administration Overview
      60. 12.13.3
      61. Financials
    85. MRFR Conclusion
      1. 13.1
      2. Key Findings
      3. View Point
      4. 14
      5. Appendix
    86. From CEO’s
    87. Unmet Needs of the Market
      1. Key Companies to Watch
      2. Prediction of Pharmaceutical Industry
    88. LIST OF TABLES
      1. Table 1
      2. Recombinant Vaccines Industry Synopsis, 2020–2027
      3. Table 2
      4. Global Recombinant Vaccines Market Estimates and Forecast,
    89. Global
      1. Recombinant Vaccines Market by Region, 2020–2027, (USD Million)
      2. Table
    90. Global Recombinant Vaccines Market by Type,
    91. Global
      1. Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      2. Table
    92. Global Recombinant Vaccines Market by End-Users, 2020–2027,
      1. (USD Million)
    93. North America Recombinant
      1. Vaccines Market by Type, 2020–2027, (USD Million)
      2. Table 9
      3. North America Recombinant Vaccines Market by Disease,
    94. North America Recombinant
      1. Vaccines Market by End-Users, 2020–2027, (USD Million)
      2. Table 11
      3. US Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
    95. US Recombinant Vaccines Market
      1. by Disease, 2020–2027, (USD Million)
    96. US Recombinant
      1. Vaccines Market by End-Users, 2020–2027, (USD Million)
      2. Table 14
      3. Canada Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
    97. Million)
    98. Canada
      1. Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      2. Table
    99. Canada Recombinant Vaccines Market by End-Users, 2020–2027,
      1. (USD Million)
    100. South America Recombinant Vaccines
      1. Market by Type, 2020–2027, (USD Million)
      2. Table 19
      3. South America Recombinant Vaccines Market by Disease, 2020–2027,
      4. (USD Million)
    101. South America Recombinant Vaccines
      1. Market by End-Users, 2020–2027, (USD Million)
    102. Europe
      1. Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      2. Table
    103. Europe Recombinant Vaccines Market by Disease, 2020–2027,
      1. (USD Million)
    104. Europe Recombinant Vaccines Market
      1. by End-Users, 2020–2027, (USD Million)
    105. Western
      1. Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      2. Table
    106. Western Europe Recombinant Vaccines Market by Disease, 2020–2027,
      1. (USD Million)
    107. Western Europe Recombinant Vaccines
      1. Market by End-Users, 2020–2027, (USD Million)
    108. Eastern
      1. Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      2. Table
    109. Eastern Europe Recombinant Vaccines Market by Disease, 2020–2027,
      1. (USD Million)
    110. Eastern Europe Recombinant Vaccines
      1. Market by End-Users, 2020–2027, (USD Million)
    111. Asia
      1. Pacific Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      2. Table
    112. Asia Pacific Recombinant Vaccines Market by Disease, 2020–2027,
      1. (USD Million)
    113. Asia Pacific Recombinant Vaccines
      1. Market by End-Users, 2020–2027, (USD Million)
    114. Middle
      1. East & Africa Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
    115. Middle East & Africa Recombinant Vaccines Market
      1. by End-Users, 2020–2027, (USD Million)
    116. LIST OF FIGURES
    117. Research Process
    118. Segmentation
      1. for Global Recombinant Vaccines Market
    119. Segmentation
      1. Market Dynamics for Recombinant Vaccines Market
    120. Global
    121. Recombinant Vaccines Market Share, by Type 2020
    122. Global
    123. Recombinant Vaccines Market Share, by End-Users, 2020
      1. Figure 6
    124. Global Recombinant Vaccines Market Share, by Region, 2020
      1. Figure 7
    125. North America Recombinant Vaccines Market Share, by Country, 2020
      1. Figure
    126. Europe Recombinant Vaccines Market Share, by Country, 2020
    127. Asia Pacific Recombinant Vaccines Market Share, by
      1. Country, 2020
    128. Middle East & Africa Recombinant
    129. Vaccines Market Share, by Country, 2020
    130. Global
      1. Recombinant Vaccines Market: Company Share Analysis, 2020 (%)
      2. Figure 12
      3. Astellas Pharma Inc: Key Financials
    131. Astellas
      1. Pharma Inc: Segmental Revenue
    132. Astellas Pharma
      1. Inc: Geographical Revenue
    133. Emergent BioSolutions,
      1. Inc.. Key Financials
    134. Emergent BioSolutions, Inc.:
      1. Segmental Revenue
    135. Emergent BioSolutions, Inc.:
      1. Geographical Revenue
    136. Pfizer, Inc.. : Key Financials
    137. Pfizer, Inc.. : Segmental Revenue
      1. Figure 20
      2. Pfizer, Inc.. : Geographical Revenue
    138. GlaxoSmithKline:
      1. Key Financials
    139. GlaxoSmithKline: Segmental Revenue
    140. GlaxoSmithKline: Geographical Revenue
      1. Figure
    141. Mitsubishi Tanabe Pharma Corporation : Key Financials
      1. Figure
    142. Mitsubishi Tanabe Pharma Corporation : Segmental Revenue
    143. Mitsubishi Tanabe Pharma Corporation . Geographical
      1. Revenue
    144. Bavarian Nordic. Key Financials
      1. Figure
    145. Bavarian Nordic. Segmental Revenue
      1. Figure 31
      2. Bavarian Nordic. Geographical Revenue

    Recombinant Vaccines Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions